214,546 Shares in BioAge Labs, Inc. $BIOA Purchased by Dimensional Fund Advisors LP

Key Points

• Dimensional Fund Advisors purchased 214,546 BioAge Labs shares valued at approximately $3.75 million, representing a 0.48% stake. Other institutions, including Geode Capital and Marshall Wace, also increased their positions.
• BioAge reported a quarterly loss of $0.58 per share, beating the analyst consensus of a $0.65 loss, while generating $2.45 million in revenue. The company remains unprofitable, with a negative net margin of 912.26%.
• Shares opened at $10.48, well below their 52-week high of $25.95. Analysts maintain a “Moderate Buy” consensus with an average price target of $36.57, although targets range from $21 to $40 and one firm rates the stock a sell.

Dimensional Fund Advisors LP acquired a new position in BioAge Labs, Inc. (NASDAQ:BIOA - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 214,546 shares of the company's stock, valued at approximately $3,746,000. Dimensional Fund Advisors LP owned 0.48% of BioAge Labs at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC boosted its position in shares of BioAge Labs by 60.8% during the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company's stock valued at $1,873,000 after buying an additional 171,426 shares during the period. Walleye Capital LLC bought a new stake in shares of BioAge Labs during the 2nd quarter worth approximately $64,000. Marshall Wace LLP lifted its stake in shares of BioAge Labs by 324.7% during the 2nd quarter. Marshall Wace LLP now owns 226,789 shares of the company's stock worth $937,000 after acquiring an additional 173,388 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in BioAge Labs by 85.6% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company's stock valued at $54,000 after acquiring an additional 5,976 shares during the period. Finally, Ameriprise Financial Inc. purchased a new position in BioAge Labs during the 2nd quarter valued at $182,000.

BioAge Labs Stock Down 1.8%

Shares of NASDAQ:BIOA opened at $10.48 on Thursday. The business's 50 day moving average is $19.70 and its 200 day moving average is $18.98. The stock has a market cap of $481.03 million, a P/E ratio of -4.40 and a beta of 0.93. BioAge Labs, Inc. has a 52-week low of $4.38 and a 52-week high of $25.95.

BioAge Labs (NASDAQ:BIOA - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.07. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%.The business had revenue of $2.45 million during the quarter. On average, sell-side analysts anticipate that BioAge Labs, Inc. will post -2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on BIOA shares. BTIG Research reiterated a "buy" rating and issued a $40.00 target price on shares of BioAge Labs in a research note on Monday, August 3rd. Jefferies Financial Group set a $21.00 target price on shares of BioAge Labs in a research note on Friday, July 31st. Roth Capital restated a "buy" rating and issued a $25.00 price target on shares of BioAge Labs in a report on Friday, July 31st. Needham & Company LLC reduced their price target on shares of BioAge Labs from $50.00 to $35.00 and set a "buy" rating on the stock in a research note on Friday, July 31st. Finally, Wall Street Zen lowered shares of BioAge Labs from a "hold" rating to a "sell" rating in a report on Sunday, May 17th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $36.57.

BioAge Labs Profile

BioAge Labs NASDAQ: BIOA is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.

Want to see what other hedge funds are holding BIOA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioAge Labs, Inc. (NASDAQ:BIOA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source